Sunday, June 10, 2007
Maker of Zimulti Has A Big Week Ahead
On Tuesday, June 12th, the FDA will for the first time reveal its views on the long-delayed diet drug Zimulti (Acomplia to the rest of the world).
The next day (June 13th), the agency's Endocrinologic and Metabolic Drug Advisory Committee, a panel of outside experts, will air various concerns about Zimulti/Acomplia and its side-effects, and vote on whether to recommend FDA approval.
Zimulti is predicted to be a blockbuster drug once approved in the United States, with sales estimates as high as $5 Billion in annual sales.
As news comes in, we'll keep you posted.
The next day (June 13th), the agency's Endocrinologic and Metabolic Drug Advisory Committee, a panel of outside experts, will air various concerns about Zimulti/Acomplia and its side-effects, and vote on whether to recommend FDA approval.
Zimulti is predicted to be a blockbuster drug once approved in the United States, with sales estimates as high as $5 Billion in annual sales.
As news comes in, we'll keep you posted.
Subscribe to Posts [Atom]
